Rigel Pharmaceuticals Inc (RIGL)
1.075
-0.05
(-4.44%)
USD |
NASDAQ |
Apr 25, 12:10
Rigel Pharmaceuticals Cash from Financing (TTM): 18.37M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 18.37M |
September 30, 2023 | 15.78M |
June 30, 2023 | 22.16M |
March 31, 2023 | 16.88M |
December 31, 2022 | 6.55M |
September 30, 2022 | 9.731M |
June 30, 2022 | 4.494M |
March 31, 2022 | 69.38M |
December 31, 2021 | 62.68M |
September 30, 2021 | 62.26M |
June 30, 2021 | 62.04M |
March 31, 2021 | 13.33M |
December 31, 2020 | 12.57M |
September 30, 2020 | 12.60M |
June 30, 2020 | 22.34M |
March 31, 2020 | 12.68M |
December 31, 2019 | 11.36M |
September 30, 2019 | 11.77M |
June 30, 2019 | 2.606M |
March 31, 2019 | 69.90M |
December 31, 2018 | 71.89M |
September 30, 2018 | 138.16M |
June 30, 2018 | 140.86M |
March 31, 2018 | 76.28M |
December 31, 2017 | 117.69M |
Date | Value |
---|---|
September 30, 2017 | 52.36M |
June 30, 2017 | 62.20M |
March 31, 2017 | 68.60M |
December 31, 2016 | 25.18M |
September 30, 2016 | 29.08M |
June 30, 2016 | 15.99M |
March 31, 2016 | 7.04M |
December 31, 2015 | 7.053M |
September 30, 2015 | 1.607M |
June 30, 2015 | 1.514M |
March 31, 2015 | 1.163M |
December 31, 2014 | 1.17M |
September 30, 2014 | 0.919M |
June 30, 2014 | 0.914M |
March 31, 2014 | 1.075M |
December 31, 2013 | 1.051M |
September 30, 2013 | 137.35M |
June 30, 2013 | 138.54M |
March 31, 2013 | 138.61M |
December 31, 2012 | 139.09M |
September 30, 2012 | 3.338M |
June 30, 2012 | 2.163M |
March 31, 2012 | 142.67M |
December 31, 2011 | 141.98M |
September 30, 2011 | 141.72M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
2.606M
Minimum
Jun 2019
69.38M
Maximum
Mar 2022
23.66M
Average
13.33M
Median
Mar 2021
Cash from Financing (TTM) Benchmarks
Nektar Therapeutics | 0.03M |
Avid Bioservices Inc | 9.72M |
Stereotaxis Inc | 0.081M |
Cara Therapeutics Inc | 38.15M |
Blueprint Medicines Corp | 119.22M |